Genomic Vision
First-half 2022 Results - Seite 3
Membre des indices CAC Mid & Small et CAC All-Tradable
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 14, 2022 under reference number R.22-0293, as updated by the amendment filed with the AMF on May 20, 2022, under number D.22-0293-A01, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
1 Accounts were approved by the Executive Board and examined by the Supervisory Board on September 28, 2022, and have been the subject of a limited review by the Company’s auditor, who issued his limited review report following the completion of the procedures required for the purposes of the publication of the Company’s H1 2022 financial report.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005655/en/
The Genomic Vision Stock at the time of publication of the news with a raise of +0,62 % to 0,090EUR on Lang & Schwarz stock exchange (29. September 2022, 17:57 Uhr).